Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Takeda Pharmaceutical Company Limited

35 indications, side-by-side phase, drug & LoA

$15.68

-0.04 (-0.25%)

A 86Pipeline Score Undervalued Pharma · Commercial
Market Cap
50.93 B
EPS
0.41
P/E Ratio
40.07 $
Value Trade
56.53 M
-2.64 %
Week
-3.16 %
1 Month
-12.68 %
3 Month
15.25 %
6 Month
-6.88 %
5 Year
-40.59 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
2.42 M
52 Week Range
12.99 - 18.90
% held by Insiders
0 %
% held by Institutions
3.12 %
Enterprise Value
77.88 B
Total Shares
3.16 B
Short %
0.15 %
Float Shares
3.16 B
Company Description
Employees:47,455
https://www.takeda.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
BLA Submission example
BLA
—
Biologics
Immunology
BLA
—
Biologics
Immunology
BLA
—
Biologics
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A86
Pipeline Score
$201.0B
Pipeline Value
Undervalued
Valuation Signal
298
Drugs Scored
13.2x
rNPV / MCap
Top 98%
Large Pharma
(rank 19 of 905)
Percentile Rank
Takeda Pharmaceutical Company Limited earns an A-grade pipeline score (86/100), with $201.6B risk-adjusted pipeline value, led by Peginesatide in Chronic Kidney Disease (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Peginesatide
Small molecule		Chronic Kidney DiseasePhase 3NCT0147897175% $18.5B COMPLETED 184 - -Feb 1, 2013 -Sep 20, 2016
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
oveporexton (TAK-861)
narcolepsy type 1
Phase 3
2025-07-14
oveporexton (TAK-861)
narcolepsy type 1
Phase 3
2025-07-14
oveporexton (TAK-861)
narcolepsy type 1
Phase 3
2025-07-14
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TAK
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TAK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TAK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TAK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TAK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TAK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-10-16 0.00 0 - - - - - -
2026-10-16 0.00 0 - - - - - -
2026-10-16 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Takeda Pharmaceutical Company Limited (TAK) News & Alerts
-
Thursday, June 11, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TAK ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Genetic Disorders #1 of 8 PHASE 3 Fazirsiran
RYTM SABS REGN
$7.95B 0.84 LEADER
CMV #1 of 3 PHASE 3 Maribavir
MRNA MRK
$0.27B 0.89 LEADER
Dengue #1 of 5 PHASE 3 Tetravalent Dengue Vaccine
NVS SNY ABT ·dev
 $2.26B 0.97 LEADER
Short Bowel Syndrome #1 of 3 PHASE 3 Teduglutide
JAGX SNN
$1.64B 0.95 LEADER
Von Willebrand Disease #1 of 5 PHASE 3 Vonicog Alfa + ADVATE
ALNY UBX COAG
$2.55B 0.85 LEADER
Thrombocytopenia #2 of 18 PHASE 3 TAK-755
NVS ARGX AMGN
$1.85B 0.94 LEADER
GERD #2 of 4 PHASE 2 Dexlansoprazole
AZN CPRX PHAT
$15.2B 0.95 CONTENDER
Myelodysplastic Syndromes #3 of 33 PHASE 3 Elritercept + Epoetin Alfa
BMY ABBV ARGX
$2.5B 0.82 CONTENDER
Stroke #3 of 23 PHASE 2 TAK-755
JNJ GRCE DMAC
$14.3B 0.93 CONTENDER
Anemia #3 of 8 PHASE 3 Elritercept + Epoetin Alfa
BMY AKBA CERS
$0.77B 0.85 CONTENDER
Multiple Myeloma #4 of 27 PHASE 3 IGI, 10%
JNJ ABBV BMY
$23.78B 0.92 LEADER
Psoriasis #4 of 15 PHASE 3 TAK-279
JNJ BMY ABBV
$26.66B 0.87 CONTENDER
Neuropathy #4 of 20 PHASE 3 TAK-771
VRTX ARGX SNY
$8.0B 0.86 CONTENDER
Psoriatic Arthritis #4 of 13 PHASE 3 Zasocitinib
JNJ ABBV BMY
—0.94 LEADER
Vitiligo #4 of 8 PHASE 2 Zasocitinib
INCY PFE ABBV
$1.2B 0.88 CONTENDER
Ulcerative Colitis #5 of 17 PHASE 3 Vedolizumab
SNY JNJ LLY
$6.5B 0.91 LEADER
Crohn's Disease #5 of 15 PHASE 3 Vedolizumab
SNY LLY ABBV
$12.67B 0.91 LEADER
Chronic Kidney Disease #6 of 27 PHASE 3 Mezagitamab
AZN LLY NVO
$96.33B 0.78 CONTENDER
Hemophilia #6 of 8 PHASE 1 AskBio009
NVO SNY PFE
$15.2B 0 FOLLOWER
Sleep Disorders #8 of 14 PHASE 2 TAK-360
LLY NVO AMGN
$3.95B 0.92 FOLLOWER
Major Depressive Disorder #9 of 31 PHASE 3 Vortioxetine
CMPS NBIX JNJ
$12.0B 0.97 CONTENDER
Myeloproliferative Neoplasms #9 of 14 PHASE 2 Elritercept + Ruxolitinib
BMY ABBV NVS
—0.69 FOLLOWER
Hidradenitis Suppurativa #10 of 13 PHASE 2 Zasocitinib
ABBV INCY NVS
$1.7B 0.69 FOLLOWER
Leukemia #12 of 64 PHASE 3 Ponatinib + Imatinib + Vincristine + Dexamethasone + Cytarabine + Methotrexate + Prednisone
AMGN LLY AZN
$4.28B 0.95 CONTENDER
Chronic Liver Disease #12 of 27 PHASE 1 TAK-781
GSK GILD MDGL
$19.9B 0.91 FOLLOWER
Lung Cancer #15 of 79 PHASE 3 TAK-788 + Pemetrexed + Cisplatin + Carboplatin
MRK GILD AMGN
$28.1B 0.91 CONTENDER
Colorectal Cancer #15 of 82 PHASE 2 fruquintinib + FOLFIRI
ABBV BMY MRK
$7.68B 0.99 CONTENDER
Lymphoma #20 of 69 PHASE 2 Brentuximab Vedotin + Cyclophosphamide + Doxorubicin + Prednisone
REGN LLY MRK
$8.52B 0.93 CONTENDER
Rare Genetic Disorders #21 of 61 PHASE 2 Idursulfase-IT + Elaprase
BMRN ASND NVS
—0.95 FOLLOWER
Rare Neurological Disorders #23 of 46 PHASE 2 SHP611
IONS BIIB SRPT
$139.4B 0.9 FOLLOWER
Non-Small Cell Lung Cancer #28 of 88 PHASE 1 TAK-788
MRK AMGN AZN
$28.1B 0.96 FOLLOWER
Ovarian Cancer #28 of 61 PHASE 1 TAK-853
MRK AZN LLY
$4.0B 0.85 FOLLOWER